TITLE

Everything from disease risk to drug regimens may be affected by ethnic background, MDs warned

AUTHOR(S)
Harrison, Pam
PUB. DATE
April 1994
SOURCE
CMAJ: Canadian Medical Association Journal;4/15/1994, Vol. 150 Issue 8, p1310
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
35493906

 

Related Articles

  • Pharmacogenetics of Cytochromes P450 in Tropical Medicine. Ribeiro, V.; Cavaco, I. // Current Drug Targets;Dec2006, Vol. 7 Issue 12, p1709 

    Drug response is affected by genetic and non-genetic factors, such as dietary compounds, sex, disease status and multiple drug therapy. Inherited determinants of drug disposition remain, however, the major cause of inter-individual differences due to pharmacogenetic polymorphism in drug...

  • Lenalidomide in Myelodysplastic Syndrome and Multiple Myeloma. Shah, Sachin R.; Tran, Thu M. // Drugs;2007, Vol. 67 Issue 13, p1869 

    The use of thalidomide is limited by adverse effects of sedation, constipation, neuropathy and thromboembolism. In order to discover more potent and less toxic immunomodulators than thalidomide, its chemical structure was modified and lenalidomide was formed. Lenalidomide is approved by the US...

  • The Myelodysplastic Syndromes: Diagnosis and Treatment. Steensma, David P.; Bennett, John M. // Mayo Clinic Proceedings;Jan2006, Vol. 81 Issue 1, p104 

    The myelodysplastic syndromes (MDS5) are common, acquired, clinically challenging hematologic conditions that are characterized by bone marrow failure and a risk of progression to acute leukemia. These disorders can arise de novo, especially in elderly patients or, less often, as a consequence...

  • Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys. Sekeres, Mikkael A.; Schoonen, W. Marieke; Kantarjian, Hagop; List, Alan; Fryzek, Jon; Paquette, Ronald; Maciejewski, Jaroslaw P. // JNCI: Journal of the National Cancer Institute;11/5/2008, Vol. 100 Issue 21, p1542 

    Background Myelodysplastic syndromes (MDS) comprise a group of pathologically and cytogenetically distinct bone marrow disorders. Little is known about the characteristics of MDS patients, including their pathological and prognostic classifications, cytopenias, transfusion and supportive care...

  • Telomerase Activity and MDS/EVI Gene Fusion in Myelodysplastic Syndrome. Correlation to the Immunohistochemical Expression of Ki-67, Bcl-2 and p53 in Bone Marrow Biopsy Samples. Jovanovik, Rubens; Janevska, Vesna; Cevreska, Lidija; Stojanoski, Zlate; Zdravkovska, Milka; Petrushevska, Gordana // Macedonian Journal of Medical Sciences;Dec2008, Vol. 1 Issue 2, p17 

    Background. Myelodysplastic syndrome (MDS) as a complex disorder comprised of 7 entities may arise as a primary disorder, or in a setting of an underlying disease, or as therapy related (secondary MDS). Some cases show MDS/EVI1 gene fusion, and some studies have pinpointed the association...

  • GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways. Guerenne, Laura; Beurlet, Stéphanie; Said, Mohamed; Gorombei, Petra; Le Pogam, Carole; Guidez, Fabien; de la Grange, Pierre; Omidvar, Nader; Vanneaux, Valérie; Mills, Ken; Mufti, Ghulam J.; Sarda-Mantel, Laure; Noguera, Maria Elena; Pla, Marika; Fenaux, Pierre; Padua, Rose Ann; Chomienne, Christine; Krief, Patricia // Journal of Hematology & Oncology;1/27/2016, Vol. 9, p1 

    Background: In spite of the recent discovery of genetic mutations in most myelodysplasic (MDS) patients, the pathophysiology of these disorders still remains poorly understood, and only few in vivo models are available to help unravel the disease. Methods: We performed global specific gene...

  • How to manage lower-risk myelodysplastic syndromes. Sekeres, M A // Leukemia (08876924);Mar2012, Vol. 26 Issue 3, p390 

    Patients with lower-risk myelodysplastic syndromes (MDSs), usually defined as having an International Prognostic Scoring System score of 1.0 or less, and/or <5% myeloblasts, comprise the majority of newly diagnosed and established MDS patients and have a survival measured in years. Most will...

  • Brittle bone drugs 'raise the risk of eye disease'. Jenny Hope // Daily Mail;4/3/2012, p7 

    WOMEN taking drugs to help prevent osteoporosis may have a higher risk of serious eye disease, researchers warn.

  • Brittle bone drugs 'raise the risk of eye disease'. Jenny Hope // Daily Mail;4/3/2012, p6 

    WOMEN taking drugs to help prevent osteoporosis may have a higher risk of serious eye disease, researchers warn.

  • Brittle bone drugs 'raise the risk of eye disease'. Jenny Hope // Daily Mail;4/3/2012, p7 

    WOMEN taking drugs to help prevent osteoporosis may have a higher risk of serious eye disease, researchers warn.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics